vimarsana.com

A team of scientists and physicians have discovered that the immune checkpoint protein VISTA can directly turn off tumor-fighting T-cells during immunotherapy and resist treatment. The study explains that VISTA can bind to a protein called LRIG1 in T cells, which was previously only thought to promote bone and fat development. When VISTA binds to LRIG1, the researchers found, LRIG1 sends signals that suppress T cell replication, survival and function. This interaction can happen between molecules on tumor cells and on T cells, molecules on healthy cells and T cells and even between molecules on the same T cell.

Related Keywords

Keman Zhang ,Tyler Alban ,Brian Gastman ,Timothy Chan ,Li Lily Wang ,Sheikha Fatima ,Stefanie Avril ,Cleveland Clinic Center ,Case Western Reserve University ,Global Center ,Science Immunology ,Cleveland Clinic ,Translational Hematology ,Precision Immuno Oncology ,Mubarak Endowed Chair ,Dia Roy ,

© 2024 Vimarsana

vimarsana.com © 2020. All Rights Reserved.